Home Featured Page 254

Featured

Latest

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork...

PT241 – Nick Meyers and Tyler Chandler of “Dosed”: Iboga and...

MindMed Begins Trading on Nasdaq

Psyched Wellness Initiates the Next Pre-Clinical Trial Study on AME-1

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for...

MindMed Becomes Second Psychedelic Drug Development Company to List on the...

PsyBio and Miami University Broaden Partnership Agreement for the Continued Advancement...

Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Mydecine to Report Full Year 2020 Financial Results on May 3,...

Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction...

1...253254255...295 Page 254 of 295

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork...

PT241 – Nick Meyers and Tyler Chandler of “Dosed”: Iboga and...

MindMed Begins Trading on Nasdaq

Psyched Wellness Initiates the Next Pre-Clinical Trial Study on AME-1

PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for...

MindMed Becomes Second Psychedelic Drug Development Company to List on the...

PsyBio and Miami University Broaden Partnership Agreement for the Continued Advancement...

Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Mydecine to Report Full Year 2020 Financial Results on May 3,...

Numinus Announces Phase 1 Clinical Trial of Natural Psilocybin Mushroom Extraction...

EDITOR PICKS

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY